O'Callaghan C H, Sykes R B, Staniforth S E
Antimicrob Agents Chemother. 1976 Aug;10(2):245-8. doi: 10.1128/AAC.10.2.245.
A cephalosporin, (6R,7R)-7-[(2R)-2-hydroxy-2-phenylacetamido]-3-(pyrid-2-yl-N-oxide) thiomethylceph-3-em-4-carboxylic acid (MCO), that could lead to a novel approach to the problem of beta-lactamase destruction is described. The compound is slightly more resistant to some beta-lactamases than is cephalothin, but it is still hydrolyzed by many to a varying degree. Hydrolysis of the beta-lactam bond of a cephalosporin releases the 3-substituent, which in MCO is itself an antibacterial agent, 2-mercaptopyridine-N-oxide. Thus, MCO has a dual mode of action, and bacteria that do not produce an effective amount of a beta-lactamase are inhibited by the intact cephalosporin, whereas those that do hydrolyze it are inhibited by the released antibacterial compound.
一种头孢菌素,即(6R,7R)-7-[(2R)-2-羟基-2-苯乙酰氨基]-3-(吡啶-2-基-N-氧化物)硫代甲基头孢-3-烯-4-羧酸(MCO),它为解决β-内酰胺酶破坏问题提供了一种新方法。该化合物对某些β-内酰胺酶的耐药性略高于头孢噻吩,但仍会被许多β-内酰胺酶不同程度地水解。头孢菌素β-内酰胺键的水解会释放3-取代基,在MCO中该取代基本身就是一种抗菌剂,即2-巯基吡啶-N-氧化物。因此,MCO具有双重作用模式,不产生有效量β-内酰胺酶的细菌会被完整的头孢菌素抑制,而那些水解该头孢菌素的细菌则会被释放出的抗菌化合物抑制。